{"id":2307,"date":"2026-06-11T16:00:00","date_gmt":"2026-06-11T19:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2307"},"modified":"2026-06-11T16:00:00","modified_gmt":"2026-06-11T19:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-anal-avancado-apr-ifl-nigro-nivolumab-chemoradiation-rapido-tnt","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-anal-avancado-apr-ifl-nigro-nivolumab-chemoradiation-rapido-tnt\/","title":{"rendered":"PGRSS anal avan: APR, IFL, Nigro, nivolumab"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica anal avan\u00e7ado que reduzem PGRSS a descarte de gaze e bisturi<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica anal avan\u00e7ado<\/strong> + CCA carcinoma canal anal escamoso 80%+adenoCa anorretal+adenoescamoso+cloacog\u00eanico+small cell raro+melanoma anal+sarcoma+GIST anal raro<\/strong> + HPV-driven 90%+HIV-AIDS related-DAA-AIN3+MSM men sex men screening DRE+citologia anal+anuscopia HRA<\/strong> + APR Miles abdominoperineal radical + TaTME + LPLND lateral pelvic<\/strong> + Nigro 1974+RTOG 9811+ACT-II 5-FU+MMC+RT modified+watch-and-wait W&W<\/strong> + nivolumab Opdivo CheckMate-358+pembrolizumab Keytruda KEYNOTE-A18+EA2176 carbo+pacli+nivo+atezolizumab BEATcc<\/strong> + tisotumab vedotin+enfortumab vedotin+RAPIDO TNT total neoadjuvant adaptado<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (CCA escamoso 80%+adenoCa+adenoescamoso+cloacog\u00eanico+small cell+melanoma anal+sarcoma+AIN3 CIS) + Grupo A4 (linfa inguinal IFL+il\u00edaca interna externa+presacral+pelvic+sentinela DSL Tc-99m+ICG) + Grupo C (Iridium-192 brachy intracavit\u00e1ria+intersticial CTV-AIN3+EBRT+IMRT+IGRT) + Grupo E (perfuro bi\u00f3psia+ARESC anuscopia high-resolution+LEEP+cone+EUA examination under anesthesia) + Lista C5 (5-FU+MMC mitomicina C+RT Nigro 1974+modified Nigro RTOG 9811+ACT-II+nivolumab Opdivo BMS CheckMate-358+pembrolizumab Keytruda Merck KEYNOTE-A18+EA2176 carbo+pacli+nivo+atezolizumab Tecentriq BEATcc+ipilimumab Yervoy+cemiplimab Libtayo Regeneron PD-1 EMPOWER-CSCC HPV+overlap+enfortumab vedotin Padcev+tisotumab vedotin Tivdak HPV-driven+balstilimab Agenus+dostarlimab Jemperli MMR-d Lista C5).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica anal avan\u00e7ado, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos anais avan\u00e7ados<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS anal avan\u00e7ado tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 CCA escamoso+AIN3<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nHPV+\/HIV+CID C21<\/td>\n<\/tr>\n
A4 IFL+pelvic+APR Miles<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nSentinela DSL+VRAM<\/td>\n<\/tr>\n
C brachy CTV-AIN3<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nIridium-192+EMBRACE-II<\/td>\n<\/tr>\n
E ARESC+LEEP+EUA<\/td>\n0,5-1,5 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nHigh-resolution anuscopia<\/td>\n<\/tr>\n
Lista C5 Nigro+nivo<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nRTOG 9811+CheckMate-358<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,5-32,5 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica anal avan\u00e7ado m\u00e9dia porte.<\/p>\n

A1 CCA escamoso + AIN3 + HPV-driven + HIV-related: o est\u00e1gio cir\u00fargico+screening<\/h2>\n

A primeira camada do PGRSS anal avan\u00e7ado \u00e9 A1. Padr\u00e3o setorial inclui (a) CCA carcinoma canal anal escamoso 80%<\/strong> com HPV-driven 90% + HIV-AIDS related-AIN3 incid\u00eancia aumentada + MSM men sex men + receptive anal intercourse + immunossuprimido p\u00f3s-transplante; (b) AIN3 anal intraepithelial neoplasia 3+CIS<\/strong> com HSIL high-grade squamous + screening DRE digital rectal exam + citologia anal Pap + anuscopia HRA high-resolution+\u00e1cido ac\u00e9tico+lugol Schiller + ASCCP recommendation HIV+ MSM screening; (c) outros tipos<\/strong> com adenoCa anorretal 15% + adenoescamoso 3% + cloacog\u00eanico 1% + small cell raro + melanoma anal 1% + sarcoma + GIST anal rar\u00edssimo; (d) estadiamento TNM 8\u00aa edi\u00e7\u00e3o+UICC<\/strong> Tis+T1<2cm+T2 2-5cm+T3>5cm+T4 invade vagina+uretra+bexiga+N0-N3+M0\/M1+CID C21+AJCC pT pN cM grading FIGO ginecol\u00f3gico; (e) biomarker comprehensive<\/strong> com PD-L1 22C3 Dako+SP142 Ventana CPS\u226510 immune-checkpoint + HPV testing + MMR\/MSI-H + TMB tumor mutational burden + comprehensive NGS FoundationOne CDx+Guardant360 ctDNA.<\/p>\n

Cl\u00ednica com A1 CCA avan\u00e7ado madura garante margem R0<\/strong> + previne recidiva regional<\/strong> + otimiza estadiamento TNM 8\u00aa+ASCCP screening HIV+ MSM<\/strong>. Como discutimos no post sobre anal<\/a>, A1 anal \u00e9 base.<\/p>\n

A4 APR Miles + IFL + LPLND + TaTME + reconstru\u00e7\u00e3o VRAM: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) APR Miles abdominoperineal resection<\/strong> com sigmoidectomia + retossigmoide + canal anal + esf\u00edncter + colostomia definitiva fim-terminal + reconstru\u00e7\u00e3o perineal VRAM rectus abdominis+gracilis flap; (b) TaTME Trans-Anal Total Mesorectal Excision<\/strong> com Sylla+Lacy 2010 + GelPOINT Path Applied Medical + retal alto+m\u00e9dio+baixo dif\u00edcil acesso TaTME + watch-and-wait W&W cCR salvage; (c) IFL Inguinal-Femoral Lymphadenectomy<\/strong> com superficial + profunda femoral + Cloquet + bilateral profil\u00e1tica + indica\u00e7\u00e3o cN+ inguinal + linfedema membro inferior 30-60% complica\u00e7\u00e3o; (d) LPLND Lateral Pelvic Lymph Node Dissection<\/strong> com obturador + il\u00edaca interna externa primitiva + presacral + nerve-sparing + asi\u00e1tico Jap\u00e3o padr\u00e3o retal baixo + redu\u00e7\u00e3o recidiva lateral 30-50%; (e) SLN sentinela DSL Dynamic Sentinel Lymph Node biopsy<\/strong> com Tc-99m + ICG indocyanine green + Catalona protocol + ultrastaging + omitir IFL completa unifocal SLN-negativo + experimental anal canal.<\/p>\n

Cl\u00ednica com A4 APR+IFL+LPLND+TaTME madura escala R0 90+%<\/strong> + escala SLN DSL omite IFL desnecess\u00e1ria<\/strong> + previne linfedema 30-60% IFL completa<\/strong>. Conex\u00e3o com retal baixa<\/a>.<\/p>\n

Nigro RTOG 9811 + ACT-II + nivolumab CheckMate-358 + KEYNOTE-A18 + EA2176 + RAPIDO TNT: o est\u00e1gio quimiorradio+imuno<\/h2>\n

A terceira camada \u00e9 Nigro+imuno. Padr\u00e3o setorial inclui (a) Nigro 1974 modificado RTOG 9811+ACT-II padr\u00e3o 1L localizado<\/strong> com 5-FU 1.000 mg\/m\u00b2 IC 96h D1-4+D29-32 + MMC mitomicina C 10 mg\/m\u00b2 IV D1+D29 + RT 45 Gy\/25 fr boost 14-19 Gy = 50,4-59 Gy + 6 semanas total + cCR 70-90%; (b) alternativa cisplatina-based<\/strong> com cisplatina+5-FU + CapeOx + carboplatina+paclitaxel raros + ACT-II UK Trial + CSPCC; (c) nivolumab Opdivo BMS CheckMate-358 PD-1<\/strong> monoterapia 2L+ recurrent CCA + ORR 24% + ipilimumab combina\u00e7\u00e3o CheckMate-358; (d) pembrolizumab Keytruda Merck KEYNOTE-A18 PD-1<\/strong> mUC overlap + KEYNOTE-826 ginecol\u00f3gico + EA2176 carbo+pacli+nivo+ipilimumab phase III intergrupos NRG-GU + InterAACT 2; (e) outras mol\u00e9culas<\/strong> atezolizumab Tecentriq BEATcc + cemiplimab Libtayo Regeneron PD-1 EMPOWER-CSCC HPV+ + balstilimab Agenus + dostarlimab Jemperli MMR-d + tisotumab vedotin Tivdak InnovativeBio Pfizer ADC tissue factor TF HPV-driven + RAPIDO TNT total neoadjuvant adaptado adenoCa retal modelo Lista C5.<\/p>\n

Cl\u00ednica com Nigro+nivolumab+pembro madura escala Nigro cCR 70-90%<\/strong> + escala CheckMate-358 nivolumab ORR 24% 2L+<\/strong> + escala EA2176 carbo+pacli+nivo phase III intergrupos<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade anal avan\u00e7ado<\/h2>\n

Cl\u00ednica anal avan s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+brachy+E+sist\u00eamico.<\/p>\n

Cl\u00ednica anal avan A1 + A4 + Nigro.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + chemoradiation.<\/p>\n

Cl\u00ednica anal avan 5 fluxos completos.<\/strong> A1+A4+brachy+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa anal avan\u00e7ado + Nigro cCR 70-90% + CheckMate-358 nivolumab ORR 24% + EA2176 phase III.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica anal avan\u00e7ado<\/h2>\n

O primeiro \u00e9 a subdimensionamento Lista C5 Nigro+imuno+ADC anal<\/strong>. Sem segrega\u00e7\u00e3o 5-FU+MMC+cisplatina+nivolumab+pembrolizumab+ipilimumab+atezolizumab+cemiplimab+balstilimab+dostarlimab+tisotumab vedotin+enfortumab vedotin + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 CCA escamoso + adenoCa + AIN3 + HPV-driven + HIV-related<\/strong>. Confunde rastreabilidade etiologia HPV+HIV + impossibilita TNM 8\u00aa+ASCCP+EUA examination + risco indica\u00e7\u00e3o inadequada (HIV+ AIDS-related vs HPV-driven vs MSM screening).<\/p>\n

O terceiro \u00e9 a falta de protocolo ARESC anuscopia high-resolution + ASCCP screening HIV+ MSM<\/strong>. Sem \u00e1cido ac\u00e9tico + lugol Schiller + bi\u00f3psia direcionada AIN3 + ASCCP recommendation MSM HIV+ + DRE digital rectal exam annual = perda detection precoce + risco progression CIS \u2192 invasive cancer.<\/p>\n

A regula\u00e7\u00e3o de PGRSS anal avan\u00e7ado no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Anal<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS anal avan\u00e7ado 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 CCA carcinoma canal anal escamoso 80%+HPV-driven 90%+HIV-AIDS related AIN3+MSM men sex men+immunossuprimido p\u00f3s-TX+adenoCa anorretal 15%+adenoescamoso 3%+cloacog\u00eanico+small cell+melanoma 1%+sarcoma+GIST+AIN3 CIS+HSIL+screening DRE+citologia anal Pap+ARESC anuscopia high-resolution+\u00e1cido ac\u00e9tico+lugol Schiller+ASCCP HIV+ MSM+TNM 8\u00aa+UICC+CID C21+PD-L1 CPS\u226510 22C3 Dako+SP142+MSI-H+TMB+FoundationOne CDx+Guardant360, A4 APR Miles abdominoperineal+sigmoidectomia+canal anal+esf\u00edncter+colostomia definitiva+VRAM rectus abdominis+gracilis+TaTME Sylla+Lacy 2010+GelPOINT Path+IFL Inguinal-Femoral superficial+profunda femoral+Cloquet+bilateral profil\u00e1tica+linfedema 30-60%+LPLND Lateral Pelvic obturador+il\u00edaca interna externa+presacral+nerve-sparing+asi\u00e1tico Jap\u00e3o+SLN DSL Tc-99m+ICG+Catalona+ultrastaging, C brachy intracavit\u00e1ria+intersticial Iridium-192+CTV-AIN3+EMBRACE-II adaptive+EBRT 50,4 Gy+IGRT+IMRT+CNEN-NN-3.05, E ARESC anuscopia high-resolution+LEEP loop electrosurgical+cone+EUA examination under anesthesia+colposcopia anal, Lista C5 Nigro 1974 modificado RTOG 9811+ACT-II 5-FU IC 96h+MMC+RT 50,4-59 Gy cCR 70-90%+cisplatina+5-FU+CapeOx+nivolumab Opdivo BMS CheckMate-358 PD-1 ORR 24%+pembrolizumab Keytruda Merck KEYNOTE-A18+EA2176 phase III intergrupos NRG-GU+atezolizumab Tecentriq BEATcc+cemiplimab Libtayo Regeneron PD-1 EMPOWER-CSCC HPV+overlap+balstilimab Agenus+dostarlimab Jemperli RUBY MMR-d+tisotumab vedotin Tivdak InnovativeBio Pfizer ADC HPV-driven+enfortumab vedotin Padcev+ipilimumab Yervoy+RAPIDO TNT total neoadjuvant adenoCa retal modelo.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS anal avan\u00e7ado: APR + IFL + Nigro + nivolumab + RAPIDO. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2306,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[3144,2712,3036,3145],"class_list":["post-2307","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-anal-avancado","tag-cirurgia-oncologica","tag-nigro","tag-nivolumab"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2307"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2307\/revisions"}],"predecessor-version":[{"id":4376,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2307\/revisions\/4376"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2306"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}